Familial features affecting the melanoma risk in CDKN2A-negative melanoma families: a study based on the Swedish Cancer Registry

References

• Salerni G, Carrera C, Lovatto L, et al. Benefits of total body photography and digital dermatoscopy (”two-step method of digital follow-up”) in the early diagnosis of melanoma in patients at high risk for melanoma. J Am Acad Dermatol. 2012;67(1):e17-27–e27. doi: 10.1016/j.jaad.2011.04.008.
   PubMed Web of Science ®Google Scholar
• Haenssle HA, Vente C, Bertsch HP, et al. Results of a surveillance programme for patients at high risk of malignant melanoma using digital and conventional dermoscopy. Eur J Cancer Prev. 2004;13(2):133–138. doi: 10.1097/00008469-200404000-00007.
   PubMed Web of Science ®Google Scholar
• Boniol M, Autier P, Gandini S. Melanoma mortality following skin cancer screening in Germany. BMJ Open. 2015;5(9):e008158. doi: 10.1136/bmjopen-2015-008158.
   PubMed Web of Science ®Google Scholar
• Watts CG, Dieng M, Morton RL, et al. Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. Br J Dermatol. 2015;172(1):33–47. doi: 10.1111/bjd.13403.
   PubMed Web of Science ®Google Scholar
• Wernli KJ, Henrikson NB, Morrison CC, et al. Screening for skin cancer in adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(4):436–447. doi: 10.1001/jama.2016.5415.
   PubMed Web of Science ®Google Scholar
• Uliasz A, Lebwohl M. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. Int J Dermatol. 2007;46(6):575–577. doi: 10.1111/j.1365-4632.2007.02704.x.
   PubMed Web of Science ®Google Scholar
• Hansson J, Bergenmar M, Hofer PA, et al. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program. J Clin Oncol. 2007;25(19):2819–2824. doi: 10.1200/JCO.2007.11.4108.
   PubMed Web of Science ®Google Scholar
• Watts CG, McLoughlin K, Goumas C, et al. Association between melanoma detected during routine skin checks and mortality. JAMA Dermatol. 2021;157(12):1425–1436. doi: 10.1001/jamadermatol.2021.3884.
   PubMed Web of Science ®Google Scholar
• Guitera P, Menzies SW, Coates E, et al. Efficiency of detecting new primary melanoma among individuals treated in a high-risk clinic for skin surveillance. JAMA Dermatol. 2021;157(5):521–530. doi: 10.1001/jamadermatol.2020.5651.
   PubMed Web of Science ®Google Scholar
• Pissa M, Helkkula T, Appelqvist F, et al. CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015–2020: implications for novel national recommendations. Acta Oncol. 2021;60(7):888–896. doi: 10.1080/0284186X.2021.1914346.
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Hoiom V, Jonsson G, et al. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet. 2014;51(8):545–552. doi: 10.1136/jmedgenet-2014-102320.
   PubMed Web of Science ®Google Scholar
• Goldstein AM, Struewing JP, Chidambaram A, et al. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst. 2000;92(12):1006–1010. doi: 10.1093/jnci/92.12.1006.
   PubMedGoogle Scholar
• Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007;44(2):99–106. doi: 10.1136/jmg.2006.043802.
   PubMed Web of Science ®Google Scholar
• Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009;61(4):677 e1-14–677.14. doi: 10.1016/j.jaad.2009.03.016.
   Web of Science ®Google Scholar
• Helgadottir H, Olsson H, Tucker MA, et al. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations. Genet Med. 2018;20(9):1087–1090. doi: 10.1038/gim.2017.216.
   PubMed Web of Science ®Google Scholar
• Swedish National Guidlines Familial Melanoma. RCC. 2022. [accessed Sep 2023]. Available from: https://kunskapsbanken.cancercentrum.se/globalassets/cancerdiagnoser/hud/vardprogram/hela-bilaga-1.-melanom-familjara-melanom.pdf
   Google Scholar
• Helgadottir H, Hoiom V, Tuominen R, et al. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies. Int J Cancer. 2015;137(9):2220–2226. doi: 10.1002/ijc.29595.
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Hoiom V, Tuominen R, et al. Germline CDKN2A mutation status and survival in familial melanoma cases. J Natl Cancer Inst. 2016;108(11):djw135. doi: 10.1093/jnci/djw135.
   Google Scholar
• Tuominen R, Engstrom PG, Helgadottir H, et al. The role of germline alterations in the DNA damage response genes BRIP1 and BRCA2 in melanoma susceptibility. Genes Chromosomes Cancer. 2016;55(7):601–611. doi: 10.1002/gcc.22363.
   PubMed Web of Science ®Google Scholar
• Platz A, Hansson J, Ringborg U. Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. Int J Cancer. 1998;78(1):13–15. doi: 10.1002/(SICI)1097-0215(19980925)78:1<13::AID-IJC3>3.0.CO;2-#.
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Schultz K, Lapins J, et al. BAP1 genetic testing among melanoma and cancer-prone families in Sweden. Acta Oncol. 2023;62(6):565–570. doi: 10.1080/0284186X.2023.2216338.
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Tuominen R, Olsson H, et al. Cancer risks and survival in patients with multiple primary melanomas: association with family history of melanoma and germline CDKN2A mutation status. J Am Acad Dermatol. 2017;77(5):893–901. doi: 10.1016/j.jaad.2017.05.050.
   PubMed Web of Science ®Google Scholar
• Armstrong BK, Cust AE. Sun exposure and skin cancer, and the puzzle of cutaneous melanoma: a perspective on fears et al. Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. American journal of epidemiology 1977;105:420-427. Cancer Epidemiol. 2017;48:147–156. doi: 10.1016/j.canep.2017.04.004.
   PubMed Web of Science ®Google Scholar
• Lindstrom L, Pawitan Y, Reilly M, et al. Estimation of genetic and environmental factors for melanoma onset using population-based family data. Statist Med. 2006;25(18):3110–3123. doi: 10.1002/sim.2266.
   PubMed Web of Science ®Google Scholar
• Hoiom V, Tuominen R, Kaller M, et al. MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters. Pigment Cell Melanoma Res. 2009;22(2):196–204. doi: 10.1111/j.1755-148X.2008.00526.x.
   PubMed Web of Science ®Google Scholar
• Demenais F, Mohamdi H, Chaudru V, et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst. 2010;102(20):1568–1583. doi: 10.1093/jnci/djq363.
   PubMedGoogle Scholar
• Law MH, Aoude LG, Duffy DL, et al. Multiplex melanoma families are enriched for polygenic risk. Hum Mol Genet. 2020;29(17):2976–2985. doi: 10.1093/hmg/ddaa156.
   PubMed Web of Science ®Google Scholar
• Potjer TP, van der Grinten TWJ, Lakeman IMM, et al. Association between a 46-SNP polygenic risk score and melanoma risk in Dutch patients with familial melanoma. J Med Genet. 2021;58(11):760–766. doi: 10.1136/jmedgenet-2020-107251.
   PubMed Web of Science ®Google Scholar
• Shi J, Yang XR, Ballew B, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 2014;46(5):482–486. doi: 10.1038/ng.2941.
   PubMed Web of Science ®Google Scholar
• Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959–961. doi: 10.1126/science.1230062.
   PubMed Web of Science ®Google Scholar
• Aoude LG, Pritchard AL, Robles-Espinoza CD, et al. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst. 2015;107(2) doi: 10.1093/jnci/dju408.
   PubMedGoogle Scholar
• Fallah M, Pukkala E, Sundquist K, et al. Familial melanoma by histology and age: joint data from five nordic countries. Eur J Cancer. 2014;50(6):1176–1183. doi: 10.1016/j.ejca.2013.12.023.
   PubMed Web of Science ®Google Scholar
• van der Rhee JI, Krijnen P, Gruis NA, et al. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. J Am Acad Dermatol. 2011;65(2):281–288. doi: 10.1016/j.jaad.2010.06.044.
   PubMed Web of Science ®Google Scholar
• Walpole S, Pritchard AL, Cebulla CM, et al. Comprehensive study of the clinical phenotype of germline BAP1 Variant-Carrying families worldwide. J Natl Cancer Inst. 2018;110(12):1328–1341. doi: 10.1093/jnci/djy171.
   PubMedGoogle Scholar